← The Wire
APGENasdaq
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1974640
Apogee Therapeutics develops and researches programs, incurring significant operating losses
red 8-K · 90d🔥 High media attention
$6.66B
Market cap
$132.61
Last close
+0.1%
1D
+0.1%
5D
3.5M
Volume
Price · last 39 sessions+58.7%
May 4L $77.75 · H $132.88Jun 29
79
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA 14AJun 26, 2026SC 13D/ASC 13D/AJun 23, 2026DEFA14ADEFA 14AJun 22, 2026DEFA14ADEFA14AJun 22, 20268-KMaterial Agreement · Shareholder VoteJun 22, 20268-KMaterial AgreementJun 22, 20268-KShareholder VoteJun 12, 20268-KMaterial Agreement · Reg FD DisclosureMay 27, 20268-KReg FD Disclosure · Company UpdateMay 27, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 20268-KExecutive ChangeApr 24, 2026SC 13D/ASC 13D/AMar 27, 20268-KMaterial AgreementMar 25, 2026424B5424B5Mar 25, 2026424B5424B5Mar 23, 20268-KReg FD Disclosure · Company UpdateMar 23, 202610-K10-KMar 2, 20268-KCompany UpdateMar 2, 2026SC 13D/ASC 13D/AJan 22, 20268-KReg FD Disclosure · Company UpdateJan 6, 202610-Q10-QNov 10, 20258-KResults of Operations · Reg FD DisclosureNov 10, 20258-KMaterial Agreement · Company UpdateOct 10, 2025424B5424B5Oct 10, 2025424B5424B5Oct 8, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KReg FD Disclosure · Company UpdateJul 7, 20258-KShareholder VoteJun 23, 202510-Q10-QMay 12, 20258-KResults of Operations · Reg FD DisclosureMay 12, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 20258-KMaterial AgreementMar 11, 20258-KResults of Operations · Reg FD DisclosureMar 3, 202510-K10-KMar 3, 20258-KReg FD Disclosure · Company UpdateFeb 3, 20258-KReg FD Disclosure · Company UpdateDec 10, 20248-KReg FD Disclosure · Company UpdateDec 2, 2024SC 13GSC 13GNov 14, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GSC 13GNov 8, 20248-KReg FD DisclosureOct 24, 2024SC 13GSC 13GOct 22, 2024SC 13GSEC SCHEDULE 13GOct 4, 20248-KReg FD Disclosure · Company UpdateAug 19, 202410-Q10-QAug 12, 20248-KResults of Operations · Company UpdateAug 12, 20248-KShareholder VoteJun 7, 2024DEFA14ADEFA14AMay 28, 20248-KExecutive Change · Reg FD DisclosureMay 28, 20248-KReg FD DisclosureMay 15, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 2024DEFA14ADEFA14AApr 24, 2024DEF 14ADEF 14AApr 24, 20248-KReg FD DisclosureMar 25, 2024424B4424B4Mar 11, 2024S-1S-1Mar 5, 20248-KReg FD DisclosureMar 5, 202410-K10-KMar 5, 20248-KResults of Operations · Reg FD DisclosureMar 5, 2024SC 13GSC 13GFeb 14, 202410-Q10-QNov 13, 20238-KResults of OperationsNov 13, 2023SC 13GSC 13GNov 3, 202310-Q10-QAug 28, 20238-KResults of OperationsAug 28, 20238-KExecutive ChangeAug 21, 2023SC 13GSC 13GAug 10, 20238-KReg FD DisclosureAug 7, 2023SC 13DSC 13DJul 28, 2023SC 13GSC 13GJul 24, 2023SC 13DSC 13DJul 21, 2023424B4424B4Jul 17, 2023S-1/AS-1/AJul 10, 2023
Insider Activity
In the 90 days to Mar 25, 2026: 4 sold $141.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Henderson JaneChief Financial Officer | Sell | 2,000 | $85.00 | $170K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,363 | $74.29 | $621K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,219 | $74.83 | $615K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 3,418 | $75.86 | $259K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 3,225 | $70.33 | $227K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,075 | $71.98 | $149K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $73.26 | $15K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 994 | $70.45 | $70K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 406 | $71.66 | $29K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $69.43 | $21K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $68.27 | $20K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 11,494 | $62.96 | $724K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 7,551 | $63.73 | $481K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 955 | $64.99 | $62K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,481 | $64.88 | $161K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,420 | $65.83 | $93K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,299 | $66.85 | $87K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $68.94 | $14K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 100 | $67.88 | $7K |
| Feb 2, 2026 | Henderson JaneChief Financial Officer | Sell | 1,108 | $66.15 | $73K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 7 reputable articles.
Investor's Business DailyAbbVie Goes On The Offensive With $10.9 Billion Takeover7d agoBarron'sWhy AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising7d agoReutersAbbVie sharpens immunology focus with $10.9 billion Apogee deal7d agoBloomberg.comAbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash7d agoCNBCStocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more7d agoBarron'sS&P 500 Futures Fall in Premarket Trading; Apogee Therapeutics, Fervo Energy Lead7d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance